Zhifei Biological: Recombinant Shingles ZFA01 Adjuvant Vaccine (CHO Cells) Approved for Clinical Trials

ZhiFei Biological announces that the recombinant shingles ZFA01 adjuvant vaccine (CHO cell), developed by its wholly-owned subsidiary Anhui ZhiFei Longke Ma Biological Pharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration. The approval permits the conduct of clinical trials to prevent shingles in populations aged 40 and above.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)